Муколитическая терапия для больных хронической обструктивной болезнью легких

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2006.
2. Мукоактивная терапия. Под ред. А.Г.Чучалина, А.С.Белевского. М.: Атмосфера, 2006; 2-4.
3. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance. Eur Respir J 1999; 13: 1177–88.
4. Moretti V, Lopez-Vidriero MT, Pavia D, Clarke SW. Relationship between bronchial reversibility and tracheobronchial clearance in patients with chronic bronchitis. Thorax 1997; 52: 176–80.
5. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. Thorax 2004; 59 (11): 992–6.
6. Машковский М.Д. Лекарственные средства: Пособие для врачей. Харьков: Торсинг, 1997; 2: 112–4.
7. Рациональная фармакотерапия заболеваний органов дыхания: Руководство для практикующих врачей. Под ред. А.Г.Чучалина. М.: Литтерра, 2004.
8. Laube B, Auchi R, Shields D et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996; 153 (2): 752–60.
9. Rosenstein BJ, Johnson CAC. Long-term follow-up of Phase III rhDNase trial. Pediatric Pulmonology 1994; Suppl. 10: 113–4. 
10. Rogers DF. Mucoactive Agents for Airway Mucus Hypersecretory Diseases. Respiratory Care 2007; 52 (9).
11. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration 1986; 50: 31–42.
12. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58: 294–8.
13. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552–60.
14. De Flora S, Grass C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 1997; 10: 1535.
15. Lemy-Debois N et al. Oral acetylcysteine in bronchopulmonary disease. Comparative clinical trial with bromhexine. Acta Ther 1978; 4: 125–32.
16. Nowak D, Antczak A, Krol M et al. Antioxidant properties of ambroxol. Free Radic Biol Med 1994; 16: 517–22.
17. Olivieri D, Zavattini G, Nomasini G et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long term multicenter trial. Respiration 1987; 51 (Suppl. 1): 42–51.
18. Hashizume T. Pulmonary alveolar proteinosis successfully treated with ambroxol in antioxidant therapy. Respir Med 2002; 41 (12): 1175–8.
19. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in antioxidant therapy. Respir Med 1998; 92: 609–23.
20. Carpagnano GE, Resta O et al. Exhaled interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monogydrate (SCMC-Lys). Eur J Pharmacol 2004; 505 (1–3): 169–75.
21. Bolser DC. Cough Suppressant and Pharmacologic Protussive Therapy: ACCP Evidence-Based Clinical Practice Guidelines. Chest 2006; 129: 238S–249S.
22. Yasuda H, Yamaya M, Sasaki T et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur Respir J 2006; 28: 51–8.
23. Donaldson SH, Bennett WD et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354 (3): 229–40.
24. Guo R, Pittler MH et al. Herbal medicines for the treatment of COPD: a systematic review. Eur Respir J 2006; 28: 330–8.

Н.Н.Мещерякова, С.Ю.Чикина